Venadaparib

N/A

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameVenadaparib
Drug Alias NameIDX-1197NOV-140101IDX-1197-HClNOV-1401 (National OncoVenture)NOV-1401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesIldong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIldong Pharmaceutical Co LtdIdience Co Ltd
Inactive CompaniesEirgen Pharma LtdSyneos Health（Beijing）Inc Ltd
Active IndicationsSolid tumoursStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A